Skip to content

Insulet PODD Payment for (Proceeds from) Other Investing Activity

Payment for (Proceeds from) Other Investing Activity at other companies

Eli Lilly logo
Eli LillyLLY
Medtronic logo
MedtronicMDT
Abbott logo
AbbottABT
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForProceedsFromOtherInvestingActivities.

The official record: Insulet’s 10-K, filed February 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's payment for (proceeds from) other investing activity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's payment for (proceeds from) other investing activity?
Insulet (PODD) reported payment for (proceeds from) other investing activity of $800K in Q4 2025.
What is the long-term trend for Insulet's payment for (proceeds from) other investing activity?
Over 2 years (2023 to 2025), Insulet's payment for (proceeds from) other investing activity has grown at a 3.3% compound annual growth rate (CAGR), from $3M to $3.2M.